{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Lymphocytic+Leukemia&page=8&q=venetoclax", "query": { "condition": "Chronic Lymphocytic Leukemia", "intervention": "venetoclax", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 107, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Lymphocytic+Leukemia&page=9&q=venetoclax&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Lymphocytic+Leukemia&page=7&q=venetoclax&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T22:38:22.607Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05536349", "title": "Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Pirtobrutinib", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Valacyclovir", "type": "DRUG" }, { "name": "Allopurinol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2022-12-20", "completion_date": "2028-04-25", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-22T22:38:22.607Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05536349" }, { "nct_id": "NCT06524375", "title": "A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "cBTKi Monotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2024-08-09", "completion_date": "2030-01-31", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-22T22:38:22.607Z", "location_count": 20, "location_summary": "Springdale, Arkansas • Aurora, Colorado • Jacksonville, Florida + 17 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT06524375" }, { "nct_id": "NCT06073821", "title": "Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "CLL" ], "interventions": [ { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 652, "start_date": "2023-11-11", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-22T22:38:22.607Z", "location_count": 40, "location_summary": "Anchorage, Alaska • Duarte, California • La Jolla, California + 35 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06073821" }, { "nct_id": "NCT02640833", "title": "A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Duvelisib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 0, "start_date": "2016-07", "completion_date": "2021-02", "has_results": false, "last_update_posted_date": "2016-07-26", "last_synced_at": "2026-10-22T22:38:22.607Z", "location_count": 10, "location_summary": "Tucson, Arizona • Chicago, Illinois • Harvey, Illinois + 7 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02640833" }, { "nct_id": "NCT04599634", "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Follicular Lymphoma", "Marginal Zone Lymphoma", "Mantle Cell Lymphoma", "Chronic Lymphocytic Lymphoma", "B-Cell Lymphoma" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Magrolimab", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Prednisone/prednisolone", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "CT Scan chest/abdomen/pelvis", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "18-FDG-PET", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2021-12-16", "completion_date": "2024-06-20", "has_results": true, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-10-22T22:38:22.607Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04599634" }, { "nct_id": "NCT02756897", "title": "Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Small Lymphocytic Lymphoma", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 234, "start_date": "2016-07-07", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-22T22:38:22.607Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02756897" }, { "nct_id": "NCT06247540", "title": "Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Transformed Chronic Lymphocytic Leukemia", "Refractory Transformed Chronic Lymphocytic Leukemia", "Richter Syndrome", "Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma", "Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-03-29", "completion_date": "2031-12-29", "has_results": false, "last_update_posted_date": "2024-02-29", "last_synced_at": "2026-10-22T22:38:22.607Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06247540" }, { "nct_id": "NCT03128879", "title": "Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2017-06-16", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-22T22:38:22.607Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03128879" }, { "nct_id": "NCT03576547", "title": "Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Philadelphia Chromosome Positive", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Refractory Acute Lymphoblastic Leukemia", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "t(9;22)" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ponatinib Hydrochloride", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2018-06-26", "completion_date": "2024-06-19", "has_results": true, "last_update_posted_date": "2025-05-08", "last_synced_at": "2026-10-22T22:38:22.607Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03576547" }, { "nct_id": "NCT05947851", "title": "A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia, Lymphocytic, Chronic, B-Cell", "Leukemia, Chronic Lymphocytic", "Small-Cell Lymphoma", "Lymphoma, Small Lymphocytic", "CLL", "SLL" ], "interventions": [ { "name": "Nemtabrutinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 735, "start_date": "2023-08-08", "completion_date": "2035-07-01", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-22T22:38:22.607Z", "location_count": 25, "location_summary": "Springdale, Arkansas • Long Beach, California • Clermont, Florida + 22 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Clermont", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05947851" } ] }